A well-studied full agonist of PPARγ is Rosiglitazone (Avandia), an effective insulin sensitizer that was generously prescribed to treat T2DM; yearly sales of Avandia reached US $3.3 billion in 2006 (27), until it was withdrawn from clinical use due to a number of harmful side effects (28, 29, 30). The gene discussed is INS; the disease is type 2 diabetes mellitus.